UBS Maintains Neutral on Corteva, Lowers Price Target to $85

Benzinga Newsdesk www.benzinga.com Negative 79.4%

Neg 79.4% Neu 0% Pos 0%

UBS analyst Joshua Spector maintains Corteva (NYSE:CTVA) with a Neutral and lowers the price target from $89 to $85.

Comments

No comments yet. Be the first!